ScinoPharm Taiwan Ltd
TWSE:1789
ScinoPharm Taiwan Ltd
Other Long-Term Assets
ScinoPharm Taiwan Ltd
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ScinoPharm Taiwan Ltd
TWSE:1789
|
Other Long-Term Assets
NT$640m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Other Long-Term Assets
NT$378.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
19%
|
CAGR 10-Years
7%
|
|
|
Formosa Laboratories Inc
TWSE:4746
|
Other Long-Term Assets
NT$98.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
6%
|
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Other Long-Term Assets
NT$233.9m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
24%
|
CAGR 10-Years
14%
|
|
|
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Other Long-Term Assets
NT$655.2m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Other Long-Term Assets
NT$209m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
ScinoPharm Taiwan Ltd
Glance View
ScinoPharm Taiwan Ltd. engages in the research, development, manufacturing, and sales of active pharmaceutical ingredients and injections. The company is headquartered in Tainan, Tainan. The company went IPO on 2010-10-29. The main products include active pharmaceutical ingredients, protein drugs, oligonucleotides, peptides, injection preparations, new small molecule drugs and other chemical raw materials. The firm is also engaged in the provision of consulting and biotechnology services for related products, the international trading of products, as well as the provision of customized full-process services such as chemical molecular component synthesis, process development and commercial mass production. The firm operates within the domestic market and to overseas markets, including the Americas, Europe, Australia and Asia.
See Also
What is ScinoPharm Taiwan Ltd's Other Long-Term Assets?
Other Long-Term Assets
640m
TWD
Based on the financial report for Dec 31, 2024, ScinoPharm Taiwan Ltd's Other Long-Term Assets amounts to 640m TWD.
What is ScinoPharm Taiwan Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
3%
Over the last year, the Other Long-Term Assets growth was -1%. The average annual Other Long-Term Assets growth rates for ScinoPharm Taiwan Ltd have been 1% over the past three years , 1% over the past five years , and 3% over the past ten years .
You don't have any saved screeners yet